# Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/epinephrine

> The FDA approved Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate), sponsored by BAXTER INTERNATIONAL INC (BAX), on March 30, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) |
| Codes |  |
| Sponsor | BAXTER INTERNATIONAL INC (BAX) https://sec-api.dev/companies/bax/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### November 5, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209359 ORIG-1 (Type 7 - Drug Already Marketed without Approved NDA): submission_status AP, submission_status_date 20191105, review_priority STANDARD; sponsor_name HOSPIRA; product EPINEPHRINE (EPINEPHRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209359%22

### September 19, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this NDA, as amended, and have determined that we cannot approve this NDA in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22214697_2025_Orig1s000OtherActionLtrs.pdf%22

### February 28, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218475 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250228, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (EPINEPHRINE BITARTRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218475%22

### March 30, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA220626 ORIG-1 (New Combination and New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260330, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product EPINEPHRINE (EPINEPHRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220626%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/epinephrine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/epinephrine

```bibtex
@misc{secapidev_pdufa_epinephrine_20261116,
  title        = {Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/epinephrine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_epinephrine_20261116","title":"Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/epinephrine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
